HAENYSESurgical & Medical Instruments & ApparatusFiscal year ends April 3
HAEMONETICS CORP
Financials through Q1 FY2027, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 6, 2026
$118.73+0.45 (+0.38%)
Close on Oct 19, 2026
- Market cap
- $5.43B
- P/E (TTM)
- 57.9
- Dividend yield
- –
HAEMONETICS CORP revenue by segment
By business segment
| Revenue | TTM Q1 27 | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | – | $588.30M | $576.51M | $576.99M | $569.91M | $564.27M | – | – | – | – | – | – | – | – |
| Blood Center | – | $221.27M | $220.86M | $234.64M | $246.72M | $261.12M | – | – | – | – | – | – | – | – |
| Plasma | – | $524.46M | $520.90M | $516.22M | $529.42M | $535.43M | – | – | – | – | – | – | – | – |
| Business Unit | – | – | – | – | – | – | – | – | – | $1.29B | $1.25B | $1.22B | – | – |
| Operating income | TTM Q1 27 | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | – | $103.74M | $95.96M | $97.42M | $90.83M | $88.98M | -$12.75M | $9.22M | $27.77M | $52.20M | $50.79M | $38.99M | – |
| Blood Center | – | $49.98M | $48.66M | $49.95M | $50.93M | $52.82M | $4.03M | $17.36M | $28.87M | $42.37M | $42.81M | $50.16M | – |
| Plasma | – | $184.80M | $191.74M | $189.24M | $191.07M | $184.51M | $81.66M | $114.38M | $147.99M | $181.97M | $155.84M | $151.75M | – |
By product or service
By region
| Revenue | TTM Q1 27 | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $997.62M | $982.18M | $978.50M | $988.45M | $1.00B | $1.01B | $1.01B | $1.00B | $981.84M | $970.01M | $949.30M | $922.60M | 73.8% | -0.7% |
| Europe | $189.67M | $185.02M | $174.40M | $170.29M | $169.31M | $175.66M | $178.43M | $171.31M | $167.98M | $160.14M | $150.36M | $152.43M | 14.0% | +12.0% |
| Rest of Asia | $85.73M | $87.21M | $88.40M | $90.97M | $94.17M | $92.31M | $97.97M | $103.31M | $105.28M | $107.54M | $107.11M | $101.63M | 6.3% | -9.0% |
| Japan | $67.41M | $68.20M | $65.90M | $63.94M | $62.35M | $62.41M | $62.78M | $61.43M | $60.02M | $58.09M | $58.35M | $59.07M | 5.0% | +8.1% |
| Other | $11.59M | $11.42M | $11.08M | $14.21M | $15.79M | $19.54M | $25.91M | $23.62M | $18.78M | $13.28M | $5.08M | $3.51M | 0.9% | -26.6% |
From the segment and revenue-disaggregation notes of Haemonetics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.